Dr. Patrick Kochanek served as on a select team of eleven scientists assembled by the U.S. Army Medical Research and Materiel Command to provide a strategic research plan for developing new pharmacologic treatments that improve outcomes after traumatic brain injury (TBI).
The working product titled “Pharmacotherapy of TBI: State of the Science and the Road Forward Report of the Department of Defense Neurotrauma Pharmacology Workgroup” was just published in the Journal of Neurotrauma. It identifies the key research gaps and informs future development of priorities for pre-clinical and clinical neurotrauma research.
Given that some of the latest estimates suggest that up to 20% of the 2.3 million U.S. servicemen and women deployed since 2001 may have suffered TBI, the development of new acute and chronic therapies is of vital importance. The project was led by Dr. Ramon Diaz-Arrastia from the Uniformed Services University for the Health Sciences and COL Wanda Salzar at Ft. Detrick, Maryland.
The manuscript is a timely synthesis that provides the reader with a very use-friendly tabular approach to many of the key studies. It should help investigators in the field to define the best possible “next steps” in both pre-clinical and clinical TBI investigations across the spectrum of injury severity.